Active Biotech’s election committee appointed

In  accordance with a  decision made by  the Annual General  Meeting held on May
5, 2011, the Election Committee shall comprise the representatives for the three
largest shareholders, as per end of September, and the Chairman of the Board.

For  the 2012 Annual General Meeting, the Election Committee shall propose Board
members and a Chairman of the Board, and fees to Board members and auditors. The
following   individuals   were   appointed   representatives   for  the  largest
shareholders and, accordingly, are members of the Election Committee:

Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Eggert Mörling, East Bay AB

Under  the leadership of  the Chairman of  the Board, Mats  Arnhög, the Election
Committee  shall prepare  proposals for  the Board  of Directors  that are to be
presented to and decided upon at the Annual General Meeting on May 10, 2012.

Lund, November 10, 2011
Active Biotech AB (publ)

Tomas Leanderson
President and CEO

About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit  for more information.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication on November 10, 2011 at 4:00 p.m.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech's election committee appointed:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE